Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study in Patients With Small Cell Lung Cancer (SCLC) of Veliparib in Combination With Topotecan

NCT03227016 is registered in ClinicalTrials.gov with Central European Society for Anticancer Drug Research as lead sponsor.

NCT NCT03227016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03227016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study in Patients With Small Cell Lung Cancer (SCLC) of Veliparib in Combination With Topotecan
Lead sponsor
Central European Society for Anticancer Drug Research
Phase
Phase 1
Overall status
Unknown status
Start date
October 31, 2016
Completion date
June 30, 2021
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer sclc